Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Dose-escalation and Expansion Study of the PD-1 x ILT4 Bispecific Antibody CDX-585 in Patients With Advanced Malignancies

NCT05788484 is registered in ClinicalTrials.gov with Celldex Therapeutics as lead sponsor.

NCT NCT05788484
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05788484 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Dose-escalation and Expansion Study of the PD-1 x ILT4 Bispecific Antibody CDX-585 in Patients With Advanced Malignancies
Lead sponsor
Celldex Therapeutics
Phase
Phase 1
Overall status
Completed
Start date
May 11, 2023
Completion date
May 21, 2025
Enrollment
20 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

bladder urothelial carcinoma, cholangiocarcinoma, colorectal cancer, esophageal cancer, fallopian tube cancer, gastric cancer, head and neck cancer, hepatic cancer, non-small cell lung cancer, other solid tumors, ovarian cancer, pancreatic cancer, primary peritoneal carcinoma, renal cell carcinoma